# FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy

Source: https://onco.cc/trials/nct02398773/  
OnCo record `nct02398773` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Fluoroestradiol F-18 in Breast cancer, run by National Cancer Institute (NCI), active and no longer recruiting.

## Summary

FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy is a phase 2 interventional study registered as NCT02398773 by National Cancer Institute (NCI), with 99 participants planned, started 2016-05-04 and due to reach its primary completion in 2026-12-31. Interventions recorded: Computed Tomography, F-18 16 Alpha-Fluoroestradiol, Laboratory Biomarker Analysis, Positron Emission Tomography. Conditions recorded: HER2/Neu Negative, Progesterone Receptor Negative, Progesterone Receptor Positive, Stage IV Breast Cancer AJCC v6 and v7.

Linked to the drug Fluoroestradiol F-18 because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02398773
- Phase: 2
- Setting: [18F] Fluoroestradiol (FES) PET as a Predictive Measure for Endocrine Therapy in Patients With Newly Diagnosed Metastatic Breast Cancer
- Sponsor: National Cancer Institute (NCI)
- Enrolled: 99

## Sources

- ClinicalTrials.gov NCT02398773: https://clinicaltrials.gov/study/NCT02398773

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- drugs: [Fluoroestradiol F-18 (FES PET)](https://onco.cc/drugs/fluoroestradiol-f18/)

---
JSON: https://onco.cc/api/v1/entities/nct02398773.json